What question did this study set out to answer?

This research aims to explore the activity of copper(II) benzyloxychalcone analogues in inhibiting SARS-CoV-2 replication.

May 7, 2026Open Access

View Full Paper

Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication

ISIgor Andrade SantosThe Pirbright Institute VGVictória Riquena GroscheUniversity of Leeds LOLaiane dos Santos OliveiraUniversidade Estadual de Campinas (UNICAMP)

Key Points

This research aims to explore the activity of copper(II) benzyloxychalcone analogues in inhibiting SARS-CoV-2 replication.
Evaluated the effects of Cu(II) benzyloxychalcone analogues on SARS-CoV-2 entry and RNA replication.
Investigated the mechanism of action involving disruption of the viral envelope and dsRNA intercalation.
Demonstrated that Cu(II) benzyloxychalcone analogues impair SARS-CoV-2 entry.
Interfered with RNA replication by intercalating into dsRNA, suggesting a dual mechanism of action.

Abstract

phen acts by impairing SARS-CoV-2 entry by disrupting the viral envelope as well as interrupting RNA replication through specifically intercalating into the dsRNA. The obtained results give us mechanistic insights into the activity of this promising Cu(II) metallodrug candidate in SARS-CoV-2 infection.

KI fragen

Bookmark

View Full Paper

Cite This Study

Santos et al. (Tue,) studied this question.

synapsesocial.com/papers/69fc2ca48b49bacb8b34812a https://doi.org/https://doi.org/10.1099/jgv.0.002245

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper